Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HK2 | P52789 | 5/20 | 0.42 |
| ▸ | HK1 | P19367 | 4/20 | 0.42 |
| ▸ | PYGB | P11216 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorozotocin SCHEMBL8539 | 1.00 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL11409480 | 1.00 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL11409484 | 1.00 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL19520816 | 0.99 | LMNA (0.63) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL10424026 | 0.93 | LMNA (0.78) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| SCHEMBL11573190 | 0.91 | LMNA (0.52) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| SCHEMBL29572633 | 0.91 | LMNA (0.52) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| SCHEMBL11573181 | 0.91 | LMNA (0.52) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| SCHEMBL11777948 | 0.89 | LMNA (0.50) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| SCHEMBL13382542 | 0.87 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240142403-A1 | Methods of Breath-Based Toxin Exposure Assessment, and Systems for Practicing the Same | DIAGNOSE EARLY, INC. | 2024-05-02 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | LMNA 4496/4885KDM4E 543/4885CYP2D6 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.